Vincerx Pharma, Inc. (VINC) |
|
0.885 -0.025 (-2.79%)
|
09-27 11:48 |
|
Open: |
0.92 |
Pre. Close: |
0.9104 |
|
High:
|
0.92 |
Low:
|
0.88 |
|
Volume:
|
2,954 |
Market Cap:
|
19(M) |
|
|
|
Technical analysis |
as of: 2023-09-27 11:50:51 AM |
|
Short-term rate:
|
  |
| Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected. |
|
Mid-term rate:
|
 |
| Target: |
Six months: 1.08 One year: 1.26 |
| Support: |
Support1: 0.75 Support2: 0.64 |
| Resistance: |
Resistance1: 0.92 Resistance2: 1.08 |
| Pivot: |
0.83  |
| Moving Average: |
MA(5): 0.9 MA(20): 0.79
MA(100): 1.21 MA(250): 1.11 |
| MACD: |
MACD(12,26): 0 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 87.4 %D(3): 90.6 |
| RSI: |
RSI(14): 53.1 |
| 52-week: |
High: 1.95 Low: 0.63 |
| Average Vol(K): |
3-Month: 135 (K) 10-Days: 41 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ VINC ] has closed below upper band by 35.0%. Bollinger Bands are 21.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0.92 - 0.93 |
0.93 - 0.93 |
|
Low:
|
0.82 - 0.83 |
0.83 - 0.83 |
|
Close:
|
0.91 - 0.92 |
0.92 - 0.93 |
|
Company Description |
|
Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. Its lead product candidate is VIP152, a cyclin-dependent kinase-9 inhibitor for treating patients with advanced cancer. The company's preclinical stage product candidates include VIP217, an oral PTEFb/CDK9 inhibitor; VIP236, a small molecule drug conjugate to treat solid tumors; and VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is headquartered in Palo Alto, California. |
Headline News |
Tue, 19 Sep 2023
Diffuse Large B-cell Lymphoma Market to Show Immense Growth by ... - GlobeNewswire
Tue, 19 Sep 2023
Vincerx Pharma to Participate at the Cantor Fitzgerald Global ... - GlobeNewswire
Thu, 14 Sep 2023
Vincerx Pharma Doses First Patient in the Phase 1 Clinical Trial ... - GlobeNewswire
Wed, 06 Sep 2023
Triple-Negative Breast Cancer Market to Accelerate Substantially ... - PR Newswire
Fri, 01 Sep 2023
Maintenance Mirvetuximab Soravtansine Plus Bevacizumab Under ... - OncLive
Tue, 22 Aug 2023
Vincerx stock gains as FDA clears blood cancer trial - Seeking Alpha
|
Financial Analysis |
| Price to Book Value: |
Neutral |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Neutral |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
21 (M) |
| Shares Float |
16 (M) |
|
% Held by Insiders
|
25.9 (%) |
|
% Held by Institutions
|
60.4 (%) |
|
Shares Short
|
199 (K) |
|
Shares Short P.Month
|
130 (K) |
Stock Financials |
|
EPS
|
-2.47 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
1.12 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-58.8 |
|
Return on Equity (ttm)
|
-113.8 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-2.7 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-54 (M) |
|
Levered Free Cash Flow
|
-34 (M) |
Stock Valuations |
|
PE Ratio
|
-0.36 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0.78 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-0.35 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
